Form 4: InMed Pharmaceuticals Director Exercises Stock Options

Andrew Hull, a director at InMed Pharmaceuticals, exercised stock options for 2 common shares on January 11, 2025.

Summary

• Andrew Hull, a director of InMed Pharmaceuticals, exercised employee stock options.
• The transaction involved the conversion of options into 2 common shares.
• The exercise price was originally in Canadian dollars (C$4,125.00) and converted to US dollars ($2,860.21) using an exchange rate of C$1.4422 = $US1.00.
• The options were exercised on January 11, 2025.
• Following the transaction, Mr. Hull directly owns 975 common shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not indicate any positive or negative sentiment. It is a neutral event.

Industry Context

This is a standard SEC Form 4 filing, which is common for company directors and officers when they transact in their company's securities. It provides transparency into insider transactions.

Comparison to Industry Standards

• This type of transaction is common among publicly traded companies, where directors and officers often receive stock options as part of their compensation.
• The reporting of this transaction is in line with SEC regulations for insider trading, similar to filings made by directors at companies like Canopy Growth or Aurora Cannabis, which also operate in the pharmaceutical and cannabis space.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it involves a small number of shares.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, InMed Pharmaceuticals, director, equity securities